Milrinone is a phosphodiesterase-3 inhibitor used to treat acute decompensated heart failure [1]. It works by increasing cyclic adenosine monophosphate (cAMP) levels in cardiac and vascular muscle, leading to increased cardiac contractility and vasodilation [2].
What is Milrinone Approved For?
Milrinone is indicated for the short-term management of patients with acute decompensated heart failure [1]. This can include patients who remain symptomatic or hemodynamically unstable despite appropriate diuretics, vasodilators, and/or inotropic agents [3].
How Does Milrinone Work?
Milrinone inhibits phosphodiesterase-3 (PDE3), an enzyme primarily found in cardiac and vascular smooth muscle [2]. By inhibiting PDE3, milrinone prevents the breakdown of cAMP. Increased cAMP levels in cardiac myocytes enhance calcium influx, leading to improved contractility (positive inotropy). In vascular smooth muscle, increased cAMP promotes relaxation, causing vasodilation [4]. This dual action of improving heart function and reducing the workload on the heart makes it effective in heart failure [1].
What Are the Risks and Side Effects of Milrinone?
The most common adverse effects associated with milrinone include arrhythmias, such as supraventricular and ventricular tachycardia, and hypotension [1]. Other reported side effects can include headache, nausea, vomiting, and chest pain [3]. Due to its potential for arrhythmias and hypotension, careful patient monitoring is essential during treatment [1].
How Long Is Milrinone Typically Administered?
Milrinone is intended for short-term use, typically administered intravenously in a hospital setting [1][3]. The duration of therapy is determined by the patient's clinical response and hemodynamic status [3].
How Does Milrinone Compare to Other Heart Failure Medications?
Milrinone is a positive inotrope and vasodilator, used in acute decompensated heart failure. Unlike beta-blockers or ACE inhibitors, which are mainstays for chronic heart failure management, milrinone is reserved for severe, acute episodes [1]. Digoxin is another inotropic agent, but it acts via a different mechanism and has a slower onset and offset [5]. Dobutamine is another intravenous inotrope used in acute heart failure, working primarily through beta-adrenergic receptors [6].
What is the Role of Milrinone in the Treatment of Heart Failure?
Milrinone serves as an option for patients with acute decompensated heart failure who require inotropic support and vasodilation when other standard treatments are insufficient [3]. It aims to improve symptoms and hemodynamic parameters, thereby stabilizing the patient during an acute exacerbation [1].
Are There Specific Patient Populations Who Should Avoid Milrinone?
Milrinone is contraindicated in patients with severe valvular heart disease or a known hypersensitivity to the drug [1]. Caution should be exercised in patients with significant hypotension [3].
What Clinical Data Supports Milrinone Use?
Clinical trials have demonstrated milrinone's efficacy in improving hemodynamic parameters such as cardiac output and pulmonary capillary wedge pressure in patients with acute heart failure [2][4]. Studies have also shown improvements in symptom relief and exercise tolerance in certain patient groups, though long-term survival benefits are not established for this acute therapy [1].
What Are the Drug Interactions with Milrinone?
Milrinone can interact with other medications that affect heart rate or blood pressure. Concurrent use with other intravenous inotropes or vasodilators should be carefully managed. Its interaction with drugs that prolong the QT interval requires consideration [3].
What is the Generic Availability and Cost of Milrinone?
Milrinone is available as a generic medication. The cost can vary depending on the healthcare facility and the specific formulation, but generic availability generally makes it more accessible than branded alternatives [7].
How is Milrinone Administered?
Milrinone is administered intravenously, typically as a loading dose followed by a continuous infusion [1]. Dosing is carefully titrated based on patient response and tolerance [3].
Sources:
[1] https://www.drugs.com/milrinone.html
[2] https://go.drugbank.com/drugs/DB00750
[3] https://www.ncbi.nlm.nih.gov/books/NBK534813/
[4] https://www.ahajournals.org/doi/10.1161/01.cir.84.suppl_4.IV-104
[5] https://www.ncbi.nlm.nih.gov/books/NBK536977/
[6] https://go.drugbank.com/drugs/DB00757
[7] https://www.goodrx.com/milrinone